USTR Initiates Section 301 Investigation Into Germany's Pharmaceutical Pricing Practices
USTR has initiated a Section 301 investigation targeting Germany's persistent underpayment for innovative pharmaceutical products, with a Federal Register notice formally opening the proceeding and inviting public comment. While no tariff actions have been imposed yet, this investigation could ultimately result in additional duties on imports of German-origin goods if USTR determines the practices are actionable.
Section 301 investigations historically lead to tariff actions. Our position is that importers sourcing goods from Germany — particularly in pharmaceuticals or related sectors — have reason to track this proceeding and to weigh supply-chain contingencies, and that the public comment process is open to any business exposed to potential retaliatory measures.
AI-assisted summary of a published CBP, USITC or Federal Register notice, with JFS CHB's position on it. For awareness only — always verify against the official notice before acting. Our position is general commentary on a published notice, not legal advice and not a binding opinion on any shipment. Nothing here creates a broker-client relationship or a duty of care, and it is not a substitute for a ruling, a licensed review of your facts, or the official notice itself.